Verrica Pharmaceuticals (VRCA) opened Q1 2026 with revenue of about US$5.0 million and a basic EPS loss of US$0.45, while trailing twelve month figures show revenue of US$37.2 million and a basic EPS loss of US$1.31. Over the past year, the company reported quarterly revenue moving from US$3.4 million in Q1 2025 to US$14.3 million in Q3 2025, then settling around the US$5.0 million mark in Q1 2026. EPS moved from a loss of US$1.03 to a small profit of US$0.02 in Q2 2025 before returning to losses. For investors, this combination of higher revenue over the trailing period and ongoing losses creates a results season in which margins and the path to cleaner profitability may matter more than headline sales.

See our full analysis for Verrica Pharmaceuticals.

With the numbers on the table, the next step is to see how this earnings profile lines up with the dominant narratives around Verrica Pharmaceuticals, and where the data either supports those stories or challenges them.

Larger losses return after near breakeven in mid 2025

• Net income moved from about US$0.2 million profit in Q2 2025 to a loss of US$9.7 million in Q1 2026, while basic EPS shifted from earnings of US$0.02 to a loss of US$0.45 over that span.
• Supporters with a bullish view focus on revenue momentum from YCANTH and future margin improvement. However, the recent swing back to sizeable quarterly losses raises a few questions:
  • The trailing twelve month loss of US$17.8 million contrasts with the earlier brief profit, so the current income statement still aligns more closely with the cautious points about rising costs and funding needs than with a quick move to sustainable profitability.
  • Bulls point to potential margin expansion over time, but the fact that analysts do not expect profitability over the next three years sits awkwardly beside this return to heavier quarterly losses.

Bulls argue that YCANTH's growth story outweighs recent losses, but it helps to see exactly where the numbers back that up and where they do not yet match the optimism. 🐂 Verrica Pharmaceuticals Bull Case

Revenue ramp to US$37.2 million LTM vs ongoing losses

• On a trailing twelve month basis, total revenue reached US$37.2 million in Q1 2026 while net income over the same period remained a loss of US$17.8 million and basic EPS over that span was a loss of US$1.31.
• Bears highlight the risk that strong top line figures may not translate into lasting profitability, and the current data gives them several concrete points to lean on:
  • Analysts expect earnings to decline about 5.7% per year over the coming years and describe the business as unprofitable for at least the next three, which sits alongside the LTM loss and reinforces the concern about earnings quality.
  • The cash position is described as supporting less than one year of implied cash runway, together with recent shareholder dilution, so even with forecast revenue growth there is a clear tension between funding needs and the path to steadier margins.

Skeptics warn that heavy dependence on one main product and a short cash runway could limit how far revenue growth translates into shareholder value. 🐻 Verrica Pharmaceuticals Bear Case

Low 3.2x P/S multiple vs rich DCF fair value

• Verrica trades on a P/S of about 3.2x compared with 20.9x for peers and 5.4x for the US pharmaceuticals industry, while a DCF fair value of about US$226.88 sits far above the current share price of US$6.95.
• Consensus narrative weighs this apparent valuation gap against the operational and financing risks flagged in the data:
  • On one side, forecast revenue growth of about 34.2% per year and the low P/S ratio both align with the idea that the stock could be pricing in less growth than some analyst scenarios, especially relative to a 16.43 consensus price target.
  • On the other, expectations for continued losses, projected earnings declines and less than a year of cash runway mean the wide distance to DCF fair value and to the analyst target needs to be viewed alongside the possibility of further dilution or funding costs.

Next Steps

To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for Verrica Pharmaceuticals on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.

With both risks and rewards in play, are you seeing more upside or downside here? To weigh those trade offs for yourself, take a closer look at the 3 key rewards and 5 important warning signs

Explore Alternatives

Verrica Pharmaceuticals pairs a trailing twelve month loss of US$17.8 million with expectations for continued unprofitability and a cash position described as covering less than one year.

If that mix of ongoing losses and a short cash runway feels uncomfortable, you can quickly compare it with companies screened for stronger finances and funding resilience in the solid balance sheet and fundamentals stocks screener (45 results).

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.